Replimune Group, a biotech company based in Framingham, has significantly increased planned layoffs from 63 to 224 employees following a regulatory setback. The additional cuts, scheduled for this week, affect primarily the Woburn headquarters and include 80 positions at the manufacturing facility in Framingham. This restructuring comes after the FDA rejected Replimune’s application for a new skin cancer treatment, citing insufficient evidence of its effectiveness. Despite the company’s disagreement with the FDA’s decision, CEO Sushil Patel stated the layoffs were a necessary measure.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://patch.com/massachusetts/framingham/after-regulatory-setback-80-framingham-biotech-workers-are-losing-their
